Hemab ApS
The purposes of this clinical study are 1. To see how the new drug (HMB-003) under study is tolerated in healthy volunteers, and if there are any important side effects. 2. To measure the amount of HMB-003 in the body after injection.
Inclusion Criteria: * Participant is aged 18 to 50 years, inclusive, at the time of signing informed consent. * Overall healthy as determined by medical evaluation including physical examination, vital signs, laboratory tests, and ECG. Exclusion Criteria: * Participant has a history of clinically significant hypersensitivity to any excipients of the study drug * Participant is pregnant, breastfeeding, or \<6 weeks postpartum. * Participant has received investigational drug or device in another clinical study within 30 days or 5 half-lives, whichever is longer, before dosing.
HMB-003 will be administered subcutaneously as a single dose
Placebo will be administered subcutaneously as a single dose of placebo.
Arctuva estimate
Verify or correct the compensation shown for this listing.